LGALS3 and prostate carcinoma: Other studies showed a decrease in the expression of the Galectin-3 in breast, ovary, prostate cancers, advanced uterine adenocarcinoma, basal cell of the skin, epithelial skin, and malignant salivary gland neoplasms, compared to the corresponding normal tissue (reviewed by 23, 26).